BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Büchel B, Rhyn P, Schürch S, Bühr C, Amstutz U, Largiadèr CR. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed Chromatogr 2013;27:7-16. [PMID: 22454320 DOI: 10.1002/bmc.2741] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Yang B, Wang C, Xie Y, Xu L, Wu X, Wu D. Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients. Cancer Sci 2018;109:777-84. [PMID: 29316075 DOI: 10.1111/cas.13500] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
2 Zahed FM, Hatamluyi B, Lorestani F, Es’haghi Z. Silver nanoparticles decorated polyaniline nanocomposite based electrochemical sensor for the determination of anticancer drug 5-fluorouracil. Journal of Pharmaceutical and Biomedical Analysis 2018;161:12-9. [DOI: 10.1016/j.jpba.2018.08.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
3 Leonhardt J, Hetzel T, Teutenberg T, Schmidt TC. Large Volume Injection of Aqueous Samples in Nano Liquid Chromatography Using Serially Coupled Columns. Chromatographia 2015;78:31-8. [DOI: 10.1007/s10337-014-2789-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
4 Byrne JD, Jajja MRN, O'Neill AT, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer Chemother Pharmacol 2018;81:991-8. [PMID: 29603014 DOI: 10.1007/s00280-018-3570-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Kováčik J, Klejdus B, Babula P. Oxidative stress, uptake and bioconversion of 5-fluorouracil in algae. Chemosphere 2014;100:116-23. [DOI: 10.1016/j.chemosphere.2013.11.074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
6 Lee KA, Kim SH, Kim EK, Ha EM, You H, Kim B, Kim MJ, Kwon Y, Ryu JH, Lee WJ. Bacterial-derived uracil as a modulator of mucosal immunity and gut-microbe homeostasis in Drosophila. Cell 2013;153:797-811. [PMID: 23663779 DOI: 10.1016/j.cell.2013.04.009] [Cited by in Crossref: 207] [Cited by in F6Publishing: 188] [Article Influence: 23.0] [Reference Citation Analysis]
7 Ghani M, Ghoreishi SM, Shahin M, Azamati M. Zeolitic imidazole framework templated synthesis of nanoporous carbon as a coating for stir bar sorptive extraction of fluorouracil and phenobarbital in human body fluids. Microchemical Journal 2019;146:798-806. [DOI: 10.1016/j.microc.2019.02.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
8 Naushad SM, Hussain T, Alrokayan SA, Kutala VK. Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population. J Gene Med 2021;23:e3289. [PMID: 33105068 DOI: 10.1002/jgm.3289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Pandey K, Dubey RS, Prasad BB. A Critical Review on Clinical Application of Separation Techniques for Selective Recognition of Uracil and 5-Fluorouracil. Indian J Clin Biochem. 2016;31:3-12. [PMID: 26855482 DOI: 10.1007/s12291-015-0482-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Tuzimski T, Petruczynik A. Review of Chromatographic Methods Coupled with Modern Detection Techniques Applied in the Therapeutic Drugs Monitoring (TDM). Molecules 2020;25:E4026. [PMID: 32899296 DOI: 10.3390/molecules25174026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
11 Kobuchi S, Ito Y, Nakano Y, Sakaeda T. Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats. Xenobiotica 2015;46:597-604. [DOI: 10.3109/00498254.2015.1100767] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bartlett MG. Editorial. Biomed Chromatogr 2015;29:641-2. [DOI: 10.1002/bmc.3379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, Largiader CR, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol. 2013;71:361-370. [PMID: 23139054 DOI: 10.1007/s00280-012-2018-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
14 Conti V, De Bellis E, Manzo V, Sabbatino F, Iannello F, Dal Piaz F, Izzo V, Charlier B, Stefanelli B, Torsiello M, Iannaccone T, Coglianese A, Colucci F, Pepe S, Filippelli A. A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature. J Pers Med 2020;10:E113. [PMID: 32899374 DOI: 10.3390/jpm10030113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
15 Gao J, Zhen R, Liao H, Zhuang W, Guo W. Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. Oncol Lett. 2018;15:7175-7181. [PMID: 29725440 DOI: 10.3892/ol.2018.8242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Akune Y, Yamada M, Shigeyasu C. Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1. Jpn J Ophthalmol 2018;62:432-7. [DOI: 10.1007/s10384-018-0603-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Focaccetti C, Bruno A, Magnani E, Bartolini D, Principi E, Dallaglio K, Bucci EO, Finzi G, Sessa F, Noonan DM, Albini A. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One. 2015;10:e0115686. [PMID: 25671635 DOI: 10.1371/journal.pone.0115686] [Cited by in Crossref: 139] [Cited by in F6Publishing: 126] [Article Influence: 19.9] [Reference Citation Analysis]
18 Freeman K, Connock M, Cummins E, Gurung T, Taylor-Phillips S, Court R, Saunders M, Clarke A, Sutcliffe P. Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. Health Technol Assess 2015;19:1-321, v-vi. [PMID: 26542268 DOI: 10.3310/hta19910] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
19 Tafzi N, Woillard J, Fleytoux A, Picard N, Marquet P. Phenotyping of Uracil and 5-Fluorouracil Metabolism Using LC-MS/MS for Prevention of Toxicity and Dose Adjustment of Fluoropyrimidines. Therapeutic Drug Monitoring 2020;42:540-7. [DOI: 10.1097/ftd.0000000000000768] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Jacobs BA, Rosing H, de Vries N, Meulendijks D, Henricks LM, Schellens JH, Beijnen JH. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. J Pharm Biomed Anal 2016;126:75-82. [PMID: 27179185 DOI: 10.1016/j.jpba.2016.04.039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
21 Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, Pesce D, Naviglio S, Spina A, Sannolo N, Caraglia M. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res 2012;31:60. [PMID: 22812382 DOI: 10.1186/1756-9966-31-60] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
22 Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther 2019;105:598-613. [PMID: 29923599 DOI: 10.1002/cpt.1124] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
23 Liu JH, Cheng YY, Hsieh CH, Tsai TH. The Herb-Drug Pharmacokinetic Interaction of 5-Fluorouracil and Its Metabolite 5-Fluoro-5,6-Dihydrouracil with a Traditional Chinese Medicine in Rats. Int J Mol Sci 2017;19:E25. [PMID: 29295501 DOI: 10.3390/ijms19010025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
24 Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N. Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers (Basel) 2018;10:E240. [PMID: 30041457 DOI: 10.3390/cancers10070240] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
25 Shaul YD, Freinkman E, Comb WC, Cantor JR, Tam WL, Thiru P, Kim D, Kanarek N, Pacold ME, Chen WW. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell. 2014;158:1094-1109. [PMID: 25171410 DOI: 10.1016/j.cell.2014.07.032] [Cited by in Crossref: 122] [Cited by in F6Publishing: 123] [Article Influence: 17.4] [Reference Citation Analysis]
26 Lima D, Calaça GN, Viana AG, Pessôa CA. Porphyran-capped gold nanoparticles modified carbon paste electrode: a simple and efficient electrochemical sensor for the sensitive determination of 5-fluorouracil. Applied Surface Science 2018;427:742-53. [DOI: 10.1016/j.apsusc.2017.08.228] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
27 Wu X, Xie Y, Wang C, Han Y, Bao X, Ma S, Yilmaz A, Yang B, Ji Y, Xu J, Liu H, Chen S, Zhang J, Yu J, Wu D. Prediction of acute GVHD and relapse by metabolic biomarkers after allogeneic hematopoietic stem cell transplantation. JCI Insight 2018;3:99672. [PMID: 29720575 DOI: 10.1172/jci.insight.99672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
28 Shipkova M, Svinarov D. LC–MS/MS as a tool for TDM services: Where are we? Clinical Biochemistry 2016;49:1009-23. [DOI: 10.1016/j.clinbiochem.2016.05.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
29 Robin T, Saint-Marcoux F, Toinon D, Tafzi N, Marquet P, El Balkhi S. Automatic quantification of uracil and dihydrouracil in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2020;1142:122038. [PMID: 32169798 DOI: 10.1016/j.jchromb.2020.122038] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Pan W, Li Y, Feng Y, Yang F, Liu H. A new sample preparation and separation combination for the precise, accurate, and simultaneous determination of uracil and dihydrouracil in human plasma by reversed-phase HPLC. J Sep Sci 2017;40:3763-70. [PMID: 28726286 DOI: 10.1002/jssc.201700279] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
31 Kobuchi S, Ito Y, Sakaeda T. Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats. Eur J Drug Metab Pharmacokinet 2017;42:707-18. [PMID: 27889876 DOI: 10.1007/s13318-016-0389-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
32 Sistonen J, Büchel B, Froehlich TK, Kummer D, Fontana S, Joerger M, van Kuilenburg AB, Largiadèr CR. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics 2014;15:1653-66. [PMID: 25410891 DOI: 10.2217/pgs.14.126] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
33 Sabourian R, Mirjalili SZ, Namini N, Chavoshy F, Hajimahmoodi M, Safavi M. HPLC methods for quantifying anticancer drugs in human samples: A systematic review. Anal Biochem 2020;610:113891. [PMID: 32763305 DOI: 10.1016/j.ab.2020.113891] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
34 Kobuchi S, Ito Y, Hayakawa T, Kuwano S, Baba A, Shinohara K, Nishimura A, Shibata N, Takada K. Semi-physiological pharmacokinetic–pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats. Xenobiotica 2014;44:804-18. [DOI: 10.3109/00498254.2014.900588] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
35 Forough M, Farhadi K, Molaei R, Khalili H, Shakeri R, Zamani A, Matin AA. Capillary electrophoresis with online stacking in combination with AgNPs@MCM-41 reinforced hollow fiber solid-liquid phase microextraction for quantitative analysis of Capecitabine and its main metabolite 5-Fluorouracil in plasma samples isolated from cancer patients. Journal of Chromatography B 2017;1040:22-37. [DOI: 10.1016/j.jchromb.2016.11.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
36 Wigle TJ, Tsvetkova EV, Welch SA, Kim RB. DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics. 2019;11. [PMID: 31052357 DOI: 10.3390/pharmaceutics11050199] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
37 Hamzic S, Schärer D, Offer SM, Meulendijks D, Nakas C, Diasio RB, Fontana S, Wehrli M, Schürch S, Amstutz U, Largiadèr CR. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity. Br J Clin Pharmacol 2021;87:3234-43. [PMID: 33491253 DOI: 10.1111/bcp.14742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Chavani O, Jensen BP, Strother RM, Florkowski CM, George PM. Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2017;142:125-35. [DOI: 10.1016/j.jpba.2017.04.055] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
39 Schneider JJ, Galettis P, Martin JH. Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine. Br J Clin Pharmacol 2021;87:317-25. [PMID: 33386659 DOI: 10.1111/bcp.14723] [Reference Citation Analysis]
40 He YS, Sun W, Wang CZ, Qi LW, Yang J, Li P, Wen XD, Yuan CS. Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats. Biomed Chromatogr 2015;29:762-7. [PMID: 25339249 DOI: 10.1002/bmc.3354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
41 Ganti V, Walker EA, Nagar S. Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine. Biomed Chromatogr 2013;27:994-1002. [PMID: 23494628 DOI: 10.1002/bmc.2893] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
42 Lamberti M, Porto S, Zappavigna S, Addeo E, Marra M, Miraglia N, Sannolo N, Vanacore D, Stiuso P, Caraglia M. A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. Toxicol Lett 2014;227:151-6. [PMID: 24704391 DOI: 10.1016/j.toxlet.2014.03.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
43 Pereira-Oliveira M, Reis-Mendes A, Carvalho F, Remião F, Bastos ML, Costa VM. Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells. Biomolecules 2019;9:E21. [PMID: 30634681 DOI: 10.3390/biom9010021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Galvão TLP, Rocha IM, Ribeiro da Silva MDMC, Ribeiro da Silva MAV. Is Uracil Aromatic? The Enthalpies of Hydrogenation in the Gaseous and Crystalline Phases, and in Aqueous Solution, as Tools to Obtain an Answer. J Phys Chem A 2013;117:5826-36. [DOI: 10.1021/jp404938u] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]